Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer

This is a multicenter, non-randomized, prospective cohort study. The purpose of the study is to identify constitutional genetic factors associated with histological response, resistance or sensibility to treatment in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. 9000 patients will be enrolled in this study. Blood samples will be collected after informed consent and inclusion in the study. Patients will be treated and followed according to the standards of their treating center. They will be followed every six months for five years.

NCT Number	NCT04638725
Lead Sponsor	Centre Paul Strauss
Conditions	HER2-positive Breast Cancer
Enrollment	9,000 participants
Start Date	2021-12-15
Primary Completion	2033-12-15 (estimated)
Study Completion	2033-12-15 (estimated)
Updated on ClinicalTrials.gov	2026-06-04